This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation | MicrobiomeTrials
← Back to trials NCT07025538
Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation SUSPENDED PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-04-29Est. Completion: 2028-06-22
Enrollment target: 42 participantsLocations City of Hope Medical Center, Duarte, California, United States Other microbiome trials you might be interested in Childhood Hematopoietic and Lymphatic System Neoplasm Childhood Malignant Solid Neoplasm
This clinical trial tests the feasibility and acceptability of the Strengthening Teen Brain Resilience Using Music (STRU…
Scottsdale, United States Est. completion Nov 1, 2028
Chronic Lymphocytic Leukemia
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-114…
Duarte, United States Est. completion Feb 2031
WHIM Warts Hypogammaglobulinemia Immunodeficiency Myelokathexis
Background:
Warts, hypogammaglobulinemia, infections and myelokathexis syndrome (WHIMs) is a rare disorder that affects…
Bethesda, United States Est. completion Dec 31, 2031